睿智医药 (300149.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

37.0x

Market Cap

CNY 4.90B

MomentumView details →

1D Return

−6.55%

YTD Return

−6.59%

RSI (14)

40.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

37.0x

Market Cap

CNY 4.90B

RSI (14)

40.5

MomentumView details →

1D Return

−6.55%

YTD Return

−6.59%

ProfitabilityView details →

Gross Margin

27.37%

Net Margin

−1.00%

EBITDA Margin

10.64%

ROE (TTM)

−0.89%

ROA (TTM)

−0.56%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

+14.37%

EPS YoY

+93.67%

FCF YoY

+41.06%

Revenue CAGR 3Y

−5.07%

EPS CAGR 3Y

−65.49%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.30x

Current Ratio

2.13x

Quick Ratio

2.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.14B

Net Income (TTM)

−11.39M

Op. CF (TTM)

221.72M

Latest newsMore news →

Ruizhi Pharmaceutical announced that its Lingang base is in a capacity expansion phase, with its GMP pilot workshop entering trial production, which will support increasing business volume.5d ago

Similar companies

阿尔特300825.SZ 联检科技301115.SZ 中胤时尚300901.SZ 百诚医药301096.SZ 诺思格301333.SZ 钢研纳克300797.SZ

Latest newsMore news →

Ruizhi Pharmaceutical announced that its Lingang base is in a capacity expansion phase, with its GMP pilot workshop entering trial production, which will support increasing business volume.5d ago